Abelacimab Prevents VTE and Bleeding Risk in Knee Replacement Abelacimab Prevents VTE and Bleeding Risk in Knee Replacement

A monoclonal antibody that inhibits factor XI effectively reduces thromboembolism risk for knee-replacement patients, a new study suggests.Medscape Medical News
Source: Medscape Orthopaedics Headlines - Category: Orthopaedics Tags: Orthopaedics News Source Type: news